<DOC>
	<DOCNO>NCT01524237</DOCNO>
	<brief_summary>This study comprise 2 part , Part A Part B , healthy male participant . Part A study investigate safety intravenous ( IV ) ketamine administration single oral dos LY2979165 ( capsule ) LY2140023 ( tablet ) . Part A complete start Part B . Part B study investigate whether different dose level LY2979165 LY2140023 , administer ketamine , result change image brain scan see ketamine alone . Brain image currently use number reason include understand brain medicine effect . Ketamine anesthetic use study activate particular region brain . The single oral dos LY2979165 use part study 20 60 mg match dummy drug ( placebo ) dose . The dos LY2140023 10 , 40 , 160 mg match placebo dose . Screening require within 28 day prior start study follow 7-14 day last dose study drug . The study last 8-weeks individual participant .</brief_summary>
	<brief_title>A Study LY2979165 LY2140023 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ketamine</mesh_term>
	<criteria>overtly healthy , righthanded , Caucasian ( nonHispanic White self report ) male , determine medical history physical examination agree use effective method birth control study period 3 month final dose study drug female partner childbearing potential , agree use 2 effective method birth control study period 3 month final dose study drug one ( 1 ) method must male female condom use conjunction spermicidal gel , foam , cream , film suppository method follow : diaphragm cervical vault cap use conjunction spermicidal gel , foam , cream , film , suppository male partner sterilization true abstinence ( line participant 's usual lifestyle choice ; withdrawal calendar method consider acceptable ) placement effective intrauterine device ( IUD ) ( Consideration give type device system use , high failure rate quote certain type ) establish use oral , injected , implanted hormonal method contraception body mass index ( BMI ) 18.0 30.0 kg/m^2 , inclusive , weigh 50.0 100.0 kg , time screen clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator venous access sufficient allow blood sample administration intravenous ( IV ) ketamine per protocol reliable willing make available duration study willing follow study procedure give write informed consent approve Lilly ethical review board ( ERB ) govern site currently enrol , complete discontinue within last 90 day , clinical trial involve investigational product ; concurrently enrol type medical research judge scientifically medically compatible study know allergy LY2979165 , LY2140023 , ketamine , related compound component formulation person previously complete withdrawn study study investigate LY2979165 LY2140023 abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study PR interval great 200 msec , QTc interval great 450 msec abnormal resting , supine blood pressure ( BP ) , define systolic blood pressure ( BP ) great 150 mm Hg diastolic BP great 85 mm Hg , heart rate ( HR ) outside range 40 85 beat per minute ( bpm ) , inclusive history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data history regularly use know drug abuse and/or show positive finding urinary drug screen show evidence significant active neuropsychiatric disease , suicidal risk ( include suicidal ideation assess Columbia Suicide Severity Rating Scale [ CSSRS ] ) first degree relative history psychosis show evidence human immunodeficiency virus ( HIV ) infection and/or positive HIV antibody show evidence hepatitis C and/or positive hepatitis C antibody show evidence hepatitis B and/or positive hepatitis B surface antigen use intend use overthecounter prescription medication within 7 day prior dose . Herbal supplement must discontinue 28 day prior first dose trial medication . At discretion investigator short drug free discontinuation period may acceptable depend precise drugs/supplements take . As exception , paracetamol acetaminophen may use dos 1 g/day donate blood 500 mL within last month average weekly alcohol intake exceed 28 unit per week , unwilling stop alcohol consumption 48 hour prior dose completion study period restrict consumption 3 unit per day duration study ( 1 unit = 190 mL beer ; 87.5 mL wine ; 25 mL distil spirit ) use tobacco nicotinecontaining product excess equivalent 5 cigarette per day unable/unwilling abide clinical research unit ( CRU ) smoking restriction admission CRU discharge study period consume caffeine equivalent 6 cup coffee per day , habitual basis , unable abide study restriction caffeine/xanthine use ( , refrain consume caffeine/xanthinecontaining drink food ( coffee , tea , cola , chocolate ) admission CRU discharge study period opinion investigator sponsor , unsuitable inclusion study Have increase risk seizure evidence history 1 seizure ( except childhood febrile seizure ) , history electroencephalogram ( EEG ) epileptiform activity , history stroke ; surgery cerebral cortex ; head trauma loss consciousness Additional criterion Part B : History claustrophobia inability tolerate mock scanner environment habituation/screening session Fulfillment magnetic resonance imaging ( MRI ) contraindication standard radiography screening questionnaire ( example , history surgery involve metal implant )</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>